Sanofi (SNY) Caps Cost of Any Insulin Product at $35 per Month; Berenberg Reaffirms Its Buy Rating

With significant upside potential, Sanofi (NASDAQ:SNY) secures a spot on our list of the 12 Best Widow and Orphan Stocks to Buy According to Analysts.

On September 29, Berenberg reaffirmed its Buy rating on Sanofi (NASDAQ:SNY) with a price target of EUR110.00, citing better returns from the company’s medication pipeline. Analysts’ estimates for the $111.7 billion market-cap pharmaceutical company range between $53 and $69, while the stock is currently trading at $45.65.

According to Berenberg, Sanofi (NASDAQ:SNY)’s 2020 pipeline cohort now yields a 10% return, but if peak sales of key drugs like amlitelimab and frexalimab double, or if duvakitug enters Phase 3, its 2025 cohort could surpass its cost of capital.

Separately, on September 26, Sanofi (NASDAQ:SNY) announced it would expand an earlier program for the uninsured by capping the cost of any insulin product at $35 per month for U.S. patients with a valid prescription, regardless of insurance status. These actions highlight Sanofi’s pipeline momentum as well as its pricing strategy, which aims to increase patient access in the United States.

Sanofi (NASDAQ:SNY) researches, develops, manufactures, and markets pharmaceutical solutions globally, providing therapies in immunology, neurology, oncology, rare diseases, vaccines, and other fields. It is one of the Best Widow and Orphan Stocks.

While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 12 Best Quantum Computing Stocks to Buy According to Wall Street Analysts.

Disclosure: None.